MPH Health Care AG

23.03.2016 - Equity Research Einzelstudie // kaufen

GBC Executive Interview – MPH Mittelständische Pharma Holding AG - english

pdf For the original study, please click here
Unternehmen: MPH Health Care AG
ISIN: DE000A0L1H32
Branche: Biotechnologie-Pharma
Rating: kaufen
Kurs bei Erstellung in €: 2,45
Kursziel in €: 5,10
Mögl. Interessenskonflikt gem. §34b Abs.1 WpHG und FinAnv: 5a;6a;11

With the publication of preliminary results for the preceding financial year 2015 MPH Mittelständische Pharma Holding AG announces sales growth to €264 million (previous year: €219.25 million). For the first time MPH reports as an investment entity according to IFRS 10. The preliminary IFRS net income from the transitional consolidation reporting amounts to about €87 million (previous year: €8.45 million). The preliminary IFRS earnings per share totalled approximately €2 (previous year: €0.19).


Wichtiger Hinweis:

Bitte beachten Sie den Disclaimer/Risikohinweis sowie die Offenlegung möglicher Interessenskonflikte nach §34b WpHG /FinAnV auf unserer Webseite.